Search

Recent advances in pharmacology and brain stimulation have led to the development of novel treatments for psychiatric disorders. These new advances have led to the development of a new subspeciality, Interventional Psychiatry. Interventional Psychiatry: Road to Novel Therapeutics reviews all specialized treatments including device-based interventions such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and deep brain stimulation (DBS). This book discusses the procedure-based pharmacologic interventions including ketamine infusion therapy and psychedelic therapies. Internationally contributed, each this book outlines the state of the field, as well as implications for training and the role of the interventional psychiatrist in treatment teams. - Introduces an innovative approach combining both well-established and innovative methodologies - Includes an in-depth description of putative mechanisms of action - Features clinician-friendly presentation of indications, contraindications, and techniques - Outlines guidelines to foster fellowships in Interventional Psychiatry

Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD. - Defines Treatment-Resistant Depression and Staging Treatment Intensity - Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions - Discusses the use of Ketamine and Esketamine for treatment-resistant depression

The Neurobiology of Bipolar Disorder: Road to Novel Therapeutics combines the basic neurobiology of bipolar disorder with discussions of the most recent advances in research, including the interacting pathways implicated in the pathophysiology of bipolar disorder, genetic approaches and the pharmacogenomics of bipolar disorder. The basic foundational understanding of the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research combine to aid advanced students and researchers in their understanding of bipolar disorder management using novel and fast-acting pharmaceutical and neuromodulatory approaches. - Aids readers in understanding bipolar disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations - Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments to novel therapeutics - Synthesizes a discussion of the cellular and molecular mechanisms underlying symptoms with clinical aspects of bipolar disorder

Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD. Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness. - Aids readers in understanding major depressive disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations - Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments, to antidepressants and novel therapeutics - Synthesizes discussions on the cellular and molecular mechanisms underlying symptoms with the clinical aspects of depression